Hidradenitis Suppurativa (HS): Current and Emerging Treatments

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: closed (20 February 2024) | Viewed by 2281

Special Issue Editor


E-Mail Website
Guest Editor
“Antonio Cardarelli” National Hospital of Naples, Naples, Italy
Interests: dermatology; hidradenitis; psoriasis; biologic drugs; dermoscopy; ultrasonography; teledermatology; melanoma; skin tumors; basal cell carcinoma; wound care; inflammatory skin disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hidradenitis suppurativa (HS) to date remains a difficult disease for the dermatologist to manage due to gaps in knowledge about its etiology. There are few therapeutic choices for the treatment of HS. To date, the only FDA-approved drug remains Adalimumab (antiTNFa).

However, recent studies on the pathogenesis of HS have made it possible to investigate new therapies. Thanks to the many clinical trials currently underway in the future, it is hoped that therapeutic choices can be expanded.

This Special Issue, entitled “Hidradenitis Suppurativa: Current and Emerging Therapies”, aims to bring together articles in which new therapies that specifically target cytokines involved in the pathogenesis of HS can be discussed. We hope that this Special Issue will expand the knowledge on this disease and invite colleagues to report their experiences.

Dr. Claudio Marasca
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Hidradenitis Suppurativa
  • treatment
  • adalimumab
  • secukinumab
  • guselkumab
  • biologic therapies
  • small molecules

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 262 KiB  
Article
Clinical Features and Response to Treatment in Elderly Subjects Affected by Hidradenitis Suppurativa: A Cohort Study
by Flaminia Antonelli, Elena Ippoliti, Elia Rosi, Chiara Moltrasio, Dalma Malvaso, Elisabetta Botti, Damiano Abeni, Valentina Dini, Maria Vittoria Cannizzaro, Manfredo Bruni, Lucia Di Nardo, Maria Concetta Fargnoli, Marco Romanelli, Luca Fania, Luca Bianchi, Angelo Valerio Marzano, Francesca Prignano, Ketty Peris and Andrea Chiricozzi
J. Clin. Med. 2023, 12(24), 7754; https://doi.org/10.3390/jcm12247754 - 18 Dec 2023
Viewed by 678
Abstract
Hidradenitis suppurativa (HS) is a chronic-relapsing inflammatory skin disease. It usually appears in the second and third decades, but a smaller proportion of patients develop late-onset HS. Geriatric HS, defined as the persistence or the development of HS after the age of 65 [...] Read more.
Hidradenitis suppurativa (HS) is a chronic-relapsing inflammatory skin disease. It usually appears in the second and third decades, but a smaller proportion of patients develop late-onset HS. Geriatric HS, defined as the persistence or the development of HS after the age of 65 years, has been poorly explored. This study aimed to investigate the clinical features, treatment management and response to therapies of HS elderly subjects (≥65 years old). We designed a multicentric observational study, gathering data from seven Italian university hospitals. Demographic and clinical data of HS patients aged over 65 years were collected at baseline, week 12 and week 24. Overall, 57 elderly subjects suffering from HS were enrolled. At baseline, disease severity was predominantly moderate-to-severe, with 45.6% of patients classified as Hurley III. The gluteal phenotype was the most frequently observed; it also appeared to affect patients’ quality of life more than other phenotypes. Gluteal involvement was detected in about half (49.1%) of cases and associated with severe stages of the disease. In terms of therapeutic response, Hurley III patients showed the persistency of higher values of mean IHS4, DLQI, itch- and pain-NRS scores compared to Hurley I/II. In conclusion, disease severity in this subpopulation appears high and treatment is often challenging. Full article
(This article belongs to the Special Issue Hidradenitis Suppurativa (HS): Current and Emerging Treatments)

Review

Jump to: Research

12 pages, 1349 KiB  
Review
The Role of FDG-PET in the Evaluation of Hidradenitis Suppurativa: A Systematic Review
by Sahithi Talasila, Eric M. Teichner, Robert C. Subtirelu, David H. Xiang, Cyrus Ayubcha, Thomas Werner, Abass Alavi and Mona-Elisabeth Revheim
J. Clin. Med. 2023, 12(17), 5491; https://doi.org/10.3390/jcm12175491 - 24 Aug 2023
Viewed by 1129
Abstract
Hidradenitis suppurativa (HS) is a chronic skin disorder characterized by nodules, comedones, and sinus tracts that often leave prominent scarring. In recent years, non-invasive imaging techniques have been used to assess the inflammatory activity, vascularization, and treatment response of lesions. Specifically, fluorine-18 fluorodeoxyglucose [...] Read more.
Hidradenitis suppurativa (HS) is a chronic skin disorder characterized by nodules, comedones, and sinus tracts that often leave prominent scarring. In recent years, non-invasive imaging techniques have been used to assess the inflammatory activity, vascularization, and treatment response of lesions. Specifically, fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scans may aid in identifying systemic inflammation in patients with HS, improving diagnosis. Inflamed hypermetabolic tissues exhibit a greater uptake of FDG due to increased glucose uptake and vascularity. A systematic review was conducted to summarize the utility of nuclear imaging techniques in the diagnosis and treatment follow-up of HS. PubMed, Scopus, and ScienceDirect databases were utilized for relevant articles discussing the utility of PET scans in managing HS. A total of 51 citations were identified in the initial search. Following the review of titles, abstracts, and duplicates, 43 articles were excluded, leaving a total of eight articles for analysis. Data were extracted from each article, encompassing the number of patients, imaging techniques employed, and final results. An analysis of the data demonstrated that FDG-PET showed evidence of identifying subclinical lesions of the disease, improving the visualization of HS, and providing an objective method of assessing severity. Full article
(This article belongs to the Special Issue Hidradenitis Suppurativa (HS): Current and Emerging Treatments)
Show Figures

Figure 1

Back to TopTop